ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt
Release Date: December 15, 2023

ClinicalTrials.gov ID: NCT04840667

Study Identification

Unique Protocol ID: SHP675-301

Brief Title: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Official Title: A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease

Secondary IDs: 2018-004689-32 [EudraCT Number]

Study Status

Record Verification: December 2023

Overall Status: Terminated [Study closed due to enrolment challenges, not for any safety issues]

Study Start: December 28, 2021 [Actual]

Primary Completion: December 16, 2022 [Actual]

Study Completion: December 16, 2022 [Actual]

Study Results

Participant Flow

Pre-assignment Details	A total of 17 participants were screened and signed informed consent but none of the participants received any treatment due to screen failures. The study was terminated by the sponsor due to enrolment challenges and no participants were treated, therefore no data were evaluated and collected to be reported in this study.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 milligram per kilogram (mg/kg) body weight of intravenous (IV) infusion every other week (EOW) for 104 weeks.

Overall Study

	REPLAGAL
Started	17
Treated	0
Completed	0
Not Completed	17
Screen failures/ Failure to meet inclusion criteria	17

Baseline Characteristics

Baseline Analysis Population Description

A total of 17 participants were screened and signed informed consent but none of the participants received any treatment due to screen failures. The study was terminated by the sponsor due to enrolment challenges and no participants were treated, therefore no data were evaluated and collected to be reported in this study.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Baseline Measures

		REPLAGAL
Overall Number of Participants		0
Age, Continuous	Unit of measure: Number Analyzed	0 participants
		---
Sex: Female, Male	Unit of	0 participants

		REPLAGAL
	measure: Number Analyzed	
	Female	---
	Male	---
Race/Ethnicity, Customized	Unit of measure: Number Analyzed	0 participants
[Not specified]		---

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Change From Baseline in Renal Function at Week 104
Measure Description	Renal function was planned to be assessed by estimated glomerular filtration rate (eGFR) using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. The eGFR was planned to be calculated by CKD-EPI formula: eGFR = 141 x min (Serum Creatinine [Scr]/κ,1)^(α) x max(Scr/κ,1)^(-1.209) x 0.993^(Age) x 1.018 (if female) x 1.159 (if black) where: Scr was serum creatinine (mg/dL); κ was 0.7 for females and 0.9 for males; α was -0.329 for females and -0.411 for males; min indicated the minimum of Scr/κ or 1; max indicated the maximum of Scr /κ or 1. Change from baseline in renal function at Week 104 was planned to be reported.
Time Frame	Baseline, Week 104

Analysis Population Description

The study was terminated by the Sponsor due to enrolment challenges. No participants were treated in this study, therefore no data were evaluated and collected for this outcome measure.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Measured Values

	REPLAGAL
Overall Number of Participants Analyzed	0

No data displayed because Outcome Measure has zero total participants analyzed.

2. Primary Outcome Measure:

Measure Title	Change From Baseline in Cardiac Structure at Week 104
Measure Description	Cardiac structure was planned to be assessed by left ventricular mass index (LVMI) using cardiac magnetic resonance imaging (cMRI). Change from baseline in cardiac structure at Week 104 was planned to be reported.
Time Frame	Baseline, Week 104

Analysis Population Description

The study was terminated by the Sponsor due to enrolment challenges. No participants were treated in this study, therefore no data were evaluated and collected for this outcome measure.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Measured Values

	REPLAGAL
Overall Number of Participants Analyzed	0

No data displayed because Outcome Measure has zero total participants analyzed.

3. Secondary Outcome Measure:

Measure Title	Annualized Rate of Change in Estimated Glomerular Filtration Rate (eGFR) up to Week 104
Measure Description	Annualized rate of change in eGFR up to Week 104 was planned to be reported.
Time Frame	From Baseline up to Week 104

Analysis Population Description

The study was terminated by the Sponsor due to enrolment challenges. No participants were treated in this study, therefore no data were evaluated and collected for this outcome measure.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Measured Values

	REPLAGAL
Overall Number of Participants Analyzed	0

No data displayed because Outcome Measure has zero total participants analyzed.

4. Secondary Outcome Measure:

Measure Title	Annualized Rate of Change in Left Ventricular Mass Index (LVMI) up to Week 104
Measure Description	Annualized rate of change in LVMI up to Week 104 was planned to be reported.
Time Frame	From Baseline up to Week 104

Analysis Population Description

The study was terminated by the Sponsor due to enrolment challenges. No participants were treated in this study, therefore no data were evaluated and collected for this outcome measure.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Measured Values

	REPLAGAL
Overall Number of Participants Analyzed	0

No data displayed because Outcome Measure has zero total participants analyzed.

5. Secondary Outcome Measure:

Measure Title	Change From Baseline in eGFR up to Week 104
Measure Description	Change from baseline in eGFR up to Week 104 was planned to be reported.
Time Frame	From Baseline up to Week 104

Analysis Population Description

The study was terminated by the Sponsor due to enrolment challenges. No participants were treated in this study, therefore no data were evaluated and collected for this outcome measure.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Measured Values

	REPLAGAL
Overall Number of Participants Analyzed	0

No data displayed because Outcome Measure has zero total participants analyzed.

6. Secondary Outcome Measure:

Measure Title	Change From Baseline in LVMI up to Week 104
Measure Description	Change from baseline in LVMI up to Week 104 was planned to be reported.
Time Frame	From Baseline up to Week 104

Analysis Population Description

The study was terminated by the Sponsor due to enrolment challenges. No participants were treated in this study, therefore no data were evaluated and collected for this outcome measure.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Measured Values

	REPLAGAL
Overall Number of Participants Analyzed	0

No data displayed because Outcome Measure has zero total participants analyzed.

7. Secondary Outcome Measure:

Measure Title	Change From Baseline in Proteinuria up to Week 104
Measure Description	Proteinuria was to be measured based on protein/creatinine ratio (PCR). Change from baseline in proteinuria up to Week 104 was planned to be reported.
Time Frame	From Baseline up to Week 104

Analysis Population Description

The study was terminated by the Sponsor due to enrolment challenges. No participants were treated in this study, therefore no data were evaluated and collected for this outcome measure.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Measured Values

	REPLAGAL
Overall Number of Participants Analyzed	0

No data displayed because Outcome Measure has zero total participants analyzed.

8. Secondary Outcome Measure:

Measure Title	Change From Baseline in Cardiac Fibrotic Segments up to Week 104
Measure Description	Change from baseline in cardiac fibrotic segments suggestive of cardiac fibrosis up to Week 104 was planned to be assessed by volume of fibrosis, measured by cMRI.
Time Frame	From Baseline up to Week 104

Analysis Population Description

The study was terminated by the Sponsor due to enrolment challenges. No participants were treated in this study, therefore no data were evaluated and collected for this outcome measure.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Measured Values

	REPLAGAL
Overall Number of Participants Analyzed	0

No data displayed because Outcome Measure has zero total participants analyzed.

9. Secondary Outcome Measure:

Measure Title	Change From Baseline in Interventricular Septal End-Diastolic Thickness and Posterior Wall Thickness in Diastole up to Week 104
Measure Description	Change from baseline in interventricular septal end-diastolic thickness and posterior wall thickness in diastole up to Week 104 was planned to be measured by cMRI.
Time Frame	From Baseline up to Week 104

Analysis Population Description

The study was terminated by the Sponsor due to enrolment challenges. No participants were treated in this study, therefore no data were evaluated and collected for this outcome measure.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Measured Values

	REPLAGAL
Overall Number of Participants Analyzed	0

No data displayed because Outcome Measure has zero total participants analyzed.

10. Secondary Outcome Measure:

Measure Title	Change From Baseline in Plasma Globotriaosylsphingosine (Lyso-Gb3) up to Week 104
Measure Description	Change from baseline in lyso-Gb3 up to Week 104 was planned to be reported.
Time Frame	From Baseline up to Week 104

Analysis Population Description

The study was terminated by the Sponsor due to enrolment challenges. No participants were treated in this study, therefore no data were evaluated and collected for this outcome measure.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Measured Values

	REPLAGAL
Overall Number of Participants Analyzed	0

No data displayed because Outcome Measure has zero total participants analyzed.

11. Secondary Outcome Measure:

Measure Title	Number of Participants With Adverse Events (AEs)
Measure Description	An adverse event (AE) is any untoward medical occurrence in a clinical investigation participants administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.

Time Frame	From start of study drug administration up to follow-up visit (i.e., up to Week 106)

Analysis Population Description

The study was terminated by the Sponsor due to enrolment challenges. No participants were treated in this study, therefore no data were evaluated and collected for this outcome measure.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Measured Values

	REPLAGAL
Overall Number of Participants Analyzed	0

No data displayed because Outcome Measure has zero total participants analyzed.

12. Secondary Outcome Measure:

Measure Title	Number of Participants Who Will Develop Anti-drug Antibodies (ADA) to REPLAGAL
Measure Description	Number of participants who will develop ADA to REPLAGAL was planned to be reported.
Time Frame	From Baseline up to Week 104

Analysis Population Description

The study was terminated by the Sponsor due to enrolment challenges. No participants were treated in this study, therefore no data were evaluated and collected for this outcome measure.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

Measured Values

	REPLAGAL
Overall Number of Participants Analyzed	0

No data displayed because Outcome Measure has zero total participants analyzed.

Reported Adverse Events

Time Frame	From start of study drug administration up to follow-up visit (i.e., up to Week 106)
Adverse Event Reporting Description	The study was terminated by the Sponsor due to enrolment challenges. No participants were treated, therefore no Death, SAE and NSAEs data were evaluated and collected to be reported in this study.

Reporting Groups

	Description
REPLAGAL	Participants were to receive REPLAGAL 0.2 mg/kg body weight of IV infusion EOW for 104 weeks.

All-Cause Mortality

	REPLAGAL
	Affected/At Risk (%)
Total All-Cause Mortality	0/0

Serious Adverse Events

	REPLAGAL
	Affected/At Risk (%)
Total	0/0

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 0%

	REPLAGAL
	Affected/At Risk (%)
Total	0/0

Limitations and Caveats

The study was terminated by the Sponsor due to enrolment challenges. No participants were evaluated, and no data were collected to be reported in this study.

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.

Results Point of Contact:

Name/Official Title: Study Director
Organization: Shire
Phone: +1 866 842 5335
Email: ClinicalTransparency@takeda.com